Pfizer presented additional mid-stage data supporting monthly dosing for berobenatide, its GLP-1 receptor agonist acquired from Metsera. At ADA 2026, Pfizer described results from VESPER-3 showing continued weight-loss momentum after patients transitioned from weekly to higher monthly doses, reaching weight reductions up to 12.1% at 28 weeks among those remaining on treatment. The company’s messaging focused on the operational advantage of a once-monthly injection while acknowledging a competitive benchmark: analysts and observers pointed to Eli Lilly’s weekly and longer-running weight-loss profile at comparable timepoints. In a separate ADA 26 dataset preview, Pfizer framed its monthly shot as effective in patients with both obesity and diabetes—adding support for label expansion discussions. The next milestones will depend on whether monthly efficacy and tolerability can close the gap with the most aggressive competitors in the pipeline.